Vincent J. Picozzi Jr, MD, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.
Vincent J. Picozzi Jr, MD, director, Pancreas Center of Excellence, physician, Division of Hematology-Oncology, Virginia Mason Medical Center, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.
The goal of treatment in localized pancreatic cancer is cure, says Picozzi. As such, implementing chemotherapy and chemoradiation in conjunction with surgery is necessary to maximize the chance of cure for patients.
However, the use of chemotherapy and chemoradiation in the neoadjuvant setting can make it difficult to determine optimal adjuvant therapy, explains Picozzi.
At the 2020 Gastrointestinal Cancers Symposium, a poster was presented on the impact of neoadjuvant chemotherapy on treatment outcomes in patients with resected pancreatic cancer.
A univariate analysis of 134 eligible patients confirmed that many variables, including pathologic response to neoadjuvant chemotherapy, have prognostic significance for overall survival. However, a multivariate analysis revealed that other factors such as tumor size, nodal involvement >20%, and tumor differentiation were independent variables that did not have prognostic value.
As such, building upon these data may shed light on how to optimize clinical decisions regarding adjuvant therapy for patients with pancreatic cancer, concludes Picozzi.